A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Status:
Not yet recruiting
Trial end date:
2032-03-15
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to measure how well imlunestrant works compared to standard
hormone therapy in participants with early breast cancer that is estrogen receptor positive
(ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken
endocrine therapy for two to five years and must have a higher-than-average risk for their
cancer to return. Study participation could last up to 10 years.